Jennifer N. Pritzker Acquires 2,000 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATECGet Rating) major shareholder Jennifer N. Pritzker bought 2,000 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The shares were acquired at an average price of $8.32 per share, for a total transaction of $16,640.00. Following the completion of the transaction, the insider now owns 5,731 shares in the company, valued at $47,681.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of ATEC stock opened at $8.50 on Wednesday. The firm has a fifty day simple moving average of $11.00 and a two-hundred day simple moving average of $11.16. The company has a debt-to-equity ratio of 4.11, a quick ratio of 2.37 and a current ratio of 3.28. Alphatec Holdings, Inc. has a 12 month low of $7.28 and a 12 month high of $16.47.

Alphatec (NASDAQ:ATECGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The medical technology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.14). Alphatec had a negative net margin of 60.83% and a negative return on equity of 121.77%. The business had revenue of $70.93 million for the quarter, compared to the consensus estimate of $67.72 million. As a group, analysts predict that Alphatec Holdings, Inc. will post -1.31 earnings per share for the current year.

A number of research analysts have recently issued reports on ATEC shares. HC Wainwright boosted their price target on shares of Alphatec from $19.00 to $20.00 in a research report on Friday, May 6th. Piper Sandler dropped their target price on shares of Alphatec from $22.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 2nd. Zacks Investment Research downgraded shares of Alphatec from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Finally, StockNews.com initiated coverage on shares of Alphatec in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $19.00.

Large investors have recently modified their holdings of the stock. LPL Financial LLC boosted its holdings in shares of Alphatec by 17.7% in the 3rd quarter. LPL Financial LLC now owns 127,629 shares of the medical technology company’s stock worth $1,556,000 after buying an additional 19,154 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in Alphatec by 5.7% during the third quarter. Deerfield Management Company L.P. Series C now owns 3,594,829 shares of the medical technology company’s stock valued at $43,821,000 after purchasing an additional 192,445 shares during the last quarter. Voya Investment Management LLC lifted its holdings in Alphatec by 4.6% during the third quarter. Voya Investment Management LLC now owns 27,702 shares of the medical technology company’s stock valued at $338,000 after purchasing an additional 1,219 shares during the last quarter. Advisor Group Holdings Inc. lifted its holdings in Alphatec by 65.4% during the fourth quarter. Advisor Group Holdings Inc. now owns 35,787 shares of the medical technology company’s stock valued at $408,000 after purchasing an additional 14,153 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Alphatec during the third quarter valued at about $4,228,000. 53.52% of the stock is currently owned by institutional investors.

About Alphatec (Get Rating)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.

Featured Stories

Insider Buying and Selling by Quarter for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.